why choose us

First received: June 19, 2023

Clinical Trial: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Relapsed Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Brief Summary: The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

Read more